Palisade Bio, Inc. PALI
At closeNov 3, 2026, 7:45 PM EST
After hours · Nov 3, 7:45 PM ET
- YTD
- -47.66%
- 1 year
- -38.50%
- Market cap
- 214.35M
- EPS (ttm)
- 0.60
- Shares out
- 2.77M
- P/E ratio
- 2.05
- Forward P/E
- -0.19
- YTD return
- -47.66%
- 1-year return
- -38.50%
- Volume
- 18.65M
- Avg volume
- 2.78M
- Open
- 1.14
- Previous close
- 1.12
- Day's range
- 1.13 – 1.25
- 52-week range
- 1.08 – 2.86
- Beta
- 1.33
- Price target
- 30.33 (+2366.1%)
2Y -1.55 (-55.76%)
Key statistics
- Enterprise value
- -8.24M
- PEG ratio
- 0.00
- Price / book
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.66M
- Total cash
- 11.35M
- Total debt
- 503.00K
- Return on equity
- -110.09%
- Short % of float
- 3.27%
- 50-day average
- 2.61
- 200-day average
- 4.17
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 30.33
- Target (high)
- 45.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -2.32 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -3.32 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -4.59 | — | — |
| Mar 26, 2024 | Dec 1, 2023 | 0.00 | -3.75 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -7.35 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -7.95 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Brookline Capital | init | — | Buy |
| Nov 13, 2024 | Maxim Group | main | Buy | Buy |
| May 1, 2024 | Maxim Group | reit | Buy | Buy |
| Apr 16, 2024 | Maxim Group | main | Buy | Buy |
| Nov 17, 2023 | Maxim Group | up | Hold | Buy |
| May 16, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- palisadebio.com
News
Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor 
Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027 
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis 
Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated 
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 - HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations 
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6 
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
Your note
Sign in to keep a note on PALI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CSIMMA CRISTINA | Director | Conversion of Exercise of derivative security | Feb 7, 2024 | 12,862 |
| DIAZ STEPHANIE | Director | Conversion of Exercise of derivative security | Feb 7, 2024 | 12,800 |
| FINLEY JOHN DAVID | Chief Executive Officer | Conversion of Exercise of derivative security | May 27, 2024 | 13,523 |
| JONES MITCHELL LAWRENCE | Officer | Conversion of Exercise of derivative security | May 27, 2024 | 3,852 |
| MCRAE ROBERT CURTIS | Chief Operating Officer | Conversion of Exercise of derivative security | Apr 2, 2023 | 625 |
| NEAL JAMES R | Director | Conversion of Exercise of derivative security | Feb 8, 2024 | 10,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 1.88% | 52,000 | 91.00K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.30% | 8,200 | 14.35K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.06% | 1,597 | 2.79K | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 140 | 245 | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 100 | 175 | Sep 29, 2024 |
| Wells Fargo & Company | 0.00% | 21 | 36 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.23% | 6,330 | 11.08K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.16% | 4,536 | 7.94K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.15% | 4,104 | 7.18K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 2,239 | 3.92K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,524 | 2.67K | Oct 30, 2024 |